DMD and Duchenne muscular dystrophy: Artificial manipulation of mRNA splicing with an antisense oligonucleotide, such as those used for Duchenne muscular dystrophy therapy to skip mutated exon of dystrophin mRNA (Matsuo, 2021), can be applied in the future to enhance exon 17 exclusion.